ABL1 T315I
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ABL1
Variant T315I
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ABL1 T315I is a gatekeeper mutation that lies within the hinge region of the protein kinase domain of the Abl1 protein (PMID: 18794843). T315I has been demonstrated to occur as a secondary resistance mutation and results in increased kinase activity, increased transformation in cell culture (PMID: 11423618, PMID: 18794843, PMID: 27890928), and distinct gene expression patterns in patient samples (PMID: 38585663) in the context of BCR-ABL1 and results in reduced catalytic efficiency (kcat/km) in an in vitro assay (PMID: 30684523), but has not been fully characterized and therefore, its effect on Abl1 protein function is unknown.
Associated Drug Resistance Y
Category Variants Paths

ABL1 mutant ABL1 T315I

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005157.6
gDNA chr9:g.130872896C>T
cDNA c.944C>T
Protein p.T315I
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005157 chr9:g.130872896C>T c.944C>T p.T315I RefSeq GRCh38/hg38
NM_005157.6 chr9:g.130872896C>T c.944C>T p.T315I RefSeq GRCh38/hg38
NM_005157.5 chr9:g.130872896C>T c.944C>T p.T315I RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04329325 Phase II Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT06629584 Phase II Asciminib Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia Recruiting USA 0
NCT01744665 Phase II Nilotinib Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5. (ENESTgoal) Completed USA 0
NCT04925479 Phase Ib/II Asciminib Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia Recruiting USA | TUR | POL | NLD | ITA | HUN | GRC | FRA | DEU 5
NCT04160546 Phase II Aspirin + Ponatinib Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) (ResToP) Active, not recruiting ESP 0
NCT03874858 Phase II Nilotinib Asciminib + Nilotinib A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia (DANTE) Active, not recruiting ITA 0
NCT02782403 Phase Ib/II Axitinib + Bosutinib Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia Terminated USA 0
NCT01593254 Phase II Imatinib Dasatinib Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) Completed USA | POL | ITA | HUN | FRA | ESP | CZE | CAN | BRA | BEL | AUT | ARG 3
NCT05384587 Phase II Asciminib Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) Active, not recruiting USA 0
NCT06163430 Phase I TERN-701 CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia Recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT01746836 Phase II Ponatinib Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib Recruiting USA 0
NCT02228382 FDA approved Bosutinib Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Terminated USA | SWE | NOR | ITA | FRA | ESP | DEU | AUT 0
NCT02629692 Phase Ib/II K0706 Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies Active, not recruiting USA | TUR | ROU | ITA | HUN | GBR | FRA | ESP | BEL 2
NCT03106779 Phase III Bosutinib Asciminib Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Completed USA | TUR | ROU | NLD | LBN | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUS | ARG 6
NCT04835584 Phase Ib/II Dasatinib + KRT-232 KRT-232 + Nilotinib KRT-232 and TKI Study in Chronic Myeloid Leukemia Recruiting USA | POL | ITA | FRA | ESP | CAN 2
NCT03459534 Phase III Radotinib A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Recruiting TUR 3
NCT02081378 Phase I Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL Completed USA | NLD | ITA | FRA | ESP | DEU | AUS 3
NCT04793399 Phase Ib/II Atezolizumab + Bosutinib Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Terminated ESP 0
NCT02311998 Phase Ib/II Bosutinib + Inotuzumab ozogamicin Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Completed USA 0
NCT03595917 Phase I Asciminib + Blinatumomab + Dasatinib + Prednisone ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Recruiting USA 0
NCT04838041 Phase II Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib Asciminib Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Recruiting USA 0
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn USA 0
NCT06236724 Phase II Asciminib Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Recruiting USA 0
NCT06423911 Phase III Bosutinib + Olverembatinib Olverembatinib Study of Olverembatinib (HQP1351) in Patients With CP-CML (POLARIS-2) Recruiting USA 0